ABBOTINDIA · Healthcare · Drug Manufacturers - Specialty & Generic
Composite scorecard: 60/100 — Quality 94 · Valuation 48 · Momentum 2
| Share price | ₹26,905.00 |
| Market cap | ₹56,374 Cr |
| P/E ratio | 37.0 |
| P/B ratio | 14.1 |
| ROE | 42.8% |
| ROCE | 41.9% |
| Dividend yield | 1.79% |
| Book value | ₹1,887.48 |
| Year | Sales | Net profit | OPM |
|---|---|---|---|
| 2026 | ₹6,927 Cr | ₹1,552 Cr | 26.3% |
| 2025 | ₹6,407 Cr | ₹1,414 Cr | 25.7% |
| 2024 | ₹5,847 Cr | ₹1,201 Cr | 24.0% |
| 2023 | ₹5,347 Cr | ₹949 Cr | 21.5% |
| 2022 | ₹4,910 Cr | ₹799 Cr | 20.9% |
Abbott India Limited, together with its subsidiaries, operates as a pharmaceutical company in India. The company offers pharmaceutical products for gastroenterology, women's health, metabolic, central nervous system, vaccines, and multispecialty, including insomnia, vitamin D deficiency, pre-term labor, and pain management. It also provides anti-infectives, cardio-diabeto, GI & hepato, hormones, neuro-psychiat, pain management, respiratory, hepatic, neuroscience, metabolics, gennext, and consumer care products. The company was formerly known as Knoll Pharmaceuticals Limited and changed its nam